Publications
5530 Results
- Journal / Conference
- ASCO :#C-770
- Year
- 1987
- Research Committee(s)
- Lymphoma
- Study Number(s)
- SWOG-8361
Toxicity and hematopoietic reserve following hemibodyirradiation (HBI) and CHOP chemotherapy for non-hodgkin's lymphoma(NHL).
- Journal / Conference
- ASCO :#C-485
- Year
- 1987
- Research Committee(s)
- Head and Neck
- Study Number(s)
- SWOG-8371
Activity and toxicity of CBDCA and CHIP in patients with recurrentand advanced head and neck cancer.
- Journal / Conference
- ASCO 6:71 (#275)
- Year
- 1987
- Research Committee(s)
- Brain
- Study Number(s)
- SWOG-8400/05
Randomized phase II trials of acivicin (AT-125 NSC 163501) andfludarabine (2-fluoro-ara-AMP, NSC 312887) (2 FLAMP) in recurrentmalignant gliomas.
- Journal / Conference
- ASCO :#C-777
- Year
- 1987
- Research Committee(s)
- Lymphoma
- Study Number(s)
- SWOG-8410
A phase II study of m-BACOD for intermediate and high grademalignant lymphomas (NHL).
- Journal / Conference
- ASCO 6:70 (#270)
- Year
- 1987
- Research Committee(s)
- Brain
- Study Number(s)
- SWOG-8415
Tamoxifen in the treatment of refracatory meningiomas A SouthwestOncology Group study.
- Journal / Conference
- ASCO :#C-491
- Year
- 1987
- Research Committee(s)
- Sarcoma
- Study Number(s)
- SWOG-8418
Phase II evaluation of cis-platinum (CDDP) in unresectablediffuse malignant mesothelioma. A Southwest Oncology Group (SWOG)study.
- Journal / Conference
- ASCO 6:137(#536)
- Year
- 1987
- Research Committee(s)
- Sarcoma
- Study Number(s)
- SWOG-8465
High-dose cisplatin (CDDP) for advanced sarcomas.
- Journal / Conference
- ASCO :#C-776
- Year
- 1987
- Research Committee(s)
- Lymphoma
- Study Number(s)
- SWOG-8503
ProMACE-CytaBOM is active with acceptable toxicity in patientswith unfavorable non-hodgkin's lymphomas: a groupwide Southwest OncologyGroup study.
- Journal / Conference
- ASH :#852
- Year
- 1987
- Research Committee(s)
- Lymphoma
- Study Number(s)
- SWOG-8508